CAMBRIDGE, Mass., March 8, 2021 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the promotion of Dr. Caroline
Kurtz to Chief Development Officer. As Chief Development
Officer, Dr. Kurtz will be responsible for portfolio strategy,
program leadership, and development of Synlogic's portfolio of
Synthetic Biotic medicines, including the company's lead assets,
SYNB1618 for Phenylketonuria (PKU) and SYNB8802 for Enteric
Hyperoxaluria.
"At Synlogic, we are advancing multiple programs rapidly towards
meaningful clinical read-outs, executing on our mission of bringing
the transformative potential of synthetic biology to medicine,"
said Aoife Brennan, M.B. Ch.B., Synlogic's President
and Chief Executive Officer. "Caroline's track record and
experience as a cross-functional leader who has advanced important
therapies from pre-clinical to commercial will be critical as our
programs continue to advance in the clinic."
"I have a passion for drug development and am excited by the
opportunity to advance both our PKU and Enteric Hyperoxaluria
candidates towards patients," said Dr. Caroline Kurtz. "Thank you to the Synlogic team
members who are working every day to translate our platform into
meaningful products for patients. With key data read-outs in PKU
and Enteric Hyperoxaluria on the horizon, I am energized by the
challenge of bringing these programs into later stages of
development while also continuing Synlogic's strong track record of
translating our science into compelling clinical candidates."
Dr. Kurtz joined Synlogic in October
2016 and is responsible for program leadership and portfolio
planning and progression. With over 25 years of experience in the
pharmaceutical industry, Dr. Kurtz has led multiple programs
through mid and late-stage clinical development, including as Vice
President and GC-C platform lead at Ironwood Pharmaceuticals, where
she drove the development of linaclotide (LINZESS®) from pre-IND
through NDA approval and life-cycle management. Dr. Kurtz received
her Ph.D. in Immunology from Harvard
University in the laboratory of Dr. John Weis and carried out post-doctoral training
in viral immunology and central nervous system demyelinating
diseases in the laboratory of Dr. Robert
Fujinami at the University of
Utah.
Synlogic also announced the promotion of Daniel Rosan
to Senior Vice President and Head of Finance and the appointment of
Dr. Jamie Austin to the role of Vice
President and Incoming Head of Regulatory Affairs.
Mr. Rosan's responsibilities will include capital markets,
investor relations, financial planning and analysis, and
accounting. Gregg Beloff will
continue as Synlogic's interim Chief Financial Officer. Mr. Rosan
brings over 20 years of health care experience in a wide variety of
business contexts. Prior to Synlogic, he spent six years at Biogen
in roles of increasing responsibility in Finance and Research &
Development. Mr. Rosan holds a BA in History from Vassar College and an MBA from Harvard Business School.
Dr. Austin will lead Regulatory Affairs at Synlogic. She has
over 15 years of industry experience, including 10 years of
consulting and business development. Prior to Synlogic, she has
served in regulatory strategy roles at several prominent
pharmaceutical and biotech companies including AstraZeneca, AbbVie,
and bluebird bio. Dr. Austin received her MS in Bioscience
Regulatory Affairs from the Johns Hopkins
University and her Ph.D. from the University of Michigan.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synlogic-announces-promotion-of-dr-caroline-kurtz-to-chief-development-officer-and-strengthening-of-leadership-team-301241988.html
SOURCE Synlogic, Inc.